Skip to main content

Advertisement

SpringerLink
Log in

A Meta-Analysis of Antibiotic Therapy for Active Ulcerative Colitis

  • Original paper
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

To systematically evaluate the efficacy of antibacterial therapy in ulcerative colitis, we carried out a meta-analysis of controlled clinical trials. Within the time period 1966 through September 2006, PUBMED, EMBASE, and SCOPUS were searched for clinical trial studies that investigated the efficacy of antibiotics in ulcerative colitis. We considered clinical remission as our key outcome of interest. Of 122 studies, 10 randomized placebo-controlled clinical trials matched our criteria and were included in the analysis (530 patients). All the studies used antibiotics as an adjunct therapy to conventional treatment of ulcerative colitis (i.e., corticosteroids and 5-aminosalycilic acid). Pooling of these trials yielded odds ratio (OR) of 2.14 (95% confidence interval [CI], 1.48–3.09; P<0.0001) in favor of antimicrobial therapy. Meta-analysis of short-term trials (5–14 days) showed a higher rate of clinical remission in patients treated with antibiotics (OR, 2.02; 95% CI, 1.36–3). These results suggest that adjunctive antibacterial therapy is effective for induction of clinical remission in ulcerative colitis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

REFERENCES

  1. Shen EH, Das KM (2004) Current therapeutic recommendations: infliximab for ulcerative colitis. J Clin Gastroenterol 38:741–745

    Article  PubMed  CAS  Google Scholar 

  2. Lichtenstein GR (2001) Is infliximab effective for induction of remission in patients with ulcerative colitis? Inflamm Bowel Dis 7:89–93

    Article  PubMed  CAS  Google Scholar 

  3. Hanauer SB, Sparrow M (2004) Therapy of ulcerative colitis. Curr Opin Gastroenterol 20:345–350

    Article  PubMed  Google Scholar 

  4. Hanauer SB (2006) Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 12:S3–S9

    Article  PubMed  Google Scholar 

  5. Andus T, Gross V (2000) Etiology and pathophysiology of inflammatory bowel disease – environmental factors. Hepatogastroenterology 47:29–43

    PubMed  CAS  Google Scholar 

  6. Koutroubakis I, Manousos ON, Meuwissen SG, Pena AS (1996) Environmental risk factors in inflammatory bowel disease. Hepatogastroenterology 43:381–393

    PubMed  CAS  Google Scholar 

  7. Sartor RB (1997) Review article: role of the enteric microflora in the pathogenesis of intestinal inflammation and arthritis. Aliment Pharmacol Ther 11 (Suppl 3):17–22, discussion 22–23

    PubMed  Google Scholar 

  8. Swidsinski A, Ladhoff A, Pernthaler A, Swidsinski S, Loening-Baucke V, Ortner M, Weber J, Hoffmann U, Schreiber S, Dietel M, Lochs H (2002) Mucosal flora in inflammatory bowel disease. Gastroenterology 122:44–54

    Article  PubMed  Google Scholar 

  9. Gionchetti P, Rizzello F, Lammers KM, Morselli C, Sollazzi L, Davies S, Tambasco R, Calabrese C, Campieri M (2006) Antibiotics and probiotics in treatment of inflammatory bowel disease. World J Gastroenterol 12:3306–3313

    PubMed  CAS  Google Scholar 

  10. Nomura T, Ohkusa T, Okayasu I, Yoshida T, Sakamoto M, Hayashi H, Benno Y, Hirai S, Hojo M, Kobayashi O, Terai T, Miwa H, Takei Y, Ogihara T, Sato N (2005) Mucosa-associated bacteria in ulcerative colitis before and after antibiotic combination therapy. Aliment Pharmacol Ther 21:1017–1027

    Article  PubMed  CAS  Google Scholar 

  11. Rizzello F, Gionchetti P, Venturi A, Ferretti M, Peruzzo S, Raspanti X, Picard M, Canova N, Palazzini E, Campieri M (1998) Rifaximin systemic absorption in patients with ulcerative colitis. Eur J Clin Pharmacol 54:91–93

    Article  PubMed  CAS  Google Scholar 

  12. Casellas F, Borruel N, Papo M, Guarner F, Antolin M, Videla S, Malagelada JR (1998) Antiinflammatory effects of enterically coated amoxicillin-clavulanic acid in active ulcerative colitis. Inflamm Bowel Dis 4:1–5

    Article  PubMed  CAS  Google Scholar 

  13. Parlak E, Dagli U, Ulker A, Alkim C, Sahin B (2001) Comparison of 5-amino salicylic acid plus glucocorticosteroid with metronidazole and ciprofloxacin in patients with active ulcerative colitis. J Clin Gastroenterol 33:85–86

    Article  PubMed  CAS  Google Scholar 

  14. Gilat T, Leichtman G, Delpre G, Eshchar J, Bar Meir S, Fireman Z (1989) A comparison of metronidazole and sulfasalazine in the maintenance of remission in patients with ulcerative colitis. J Clin Gastroenterol 11:392–395

    Article  PubMed  CAS  Google Scholar 

  15. Gilat T, Suissa A, Leichtman G, Delpre G, Pavlotzky M, Grossman A, Fireman Z (1987) A comparative study of metronidazole and sulfasalazine in active, not severe, ulcerative colitis. An Israeli multicenter trial. J Clin Gastroenterol 9:415–417

    Article  PubMed  CAS  Google Scholar 

  16. Ohkusa T, Nomura T, Terai T, Miwa H, Kobayashi O, Hojo M, Takei Y, Ogihara T, Hirai S, Okayasu I, Sato N (2005) Effectiveness of antibiotic ombination therapy in patients with active ulcerative colitis: a randomized, controlled pilot trial with long-term follow-up. Scand J Gastroenterol 40:1334–1342

    Article  PubMed  CAS  Google Scholar 

  17. Mantzaris GJ, Archavlis E, Christoforidis P, Kourtessas D, Amberiadis P, Florakis N, Petraki K, Spiliadi C, Triantafyllou G (1997) A prospective randomized controlled trial of oral ciprofloxacin in acute ulcerative colitis. Am J Gastroenterol 92:454–456

    PubMed  CAS  Google Scholar 

  18. Burke DA, Axon AT, Clayden SA, Dixon MF, Johnston D, Lacey RW (1990) The efficacy of tobramycin in the treatment of ulcerative colitis. Aliment Pharmacol Ther 4:123–129

    Article  PubMed  CAS  Google Scholar 

  19. Gionchetti P, Rizzello F, Ferrieri A, Venturi A, Brignola C, Ferretti M, Peruzzo S, Miglioli M, Campieri M (1999) Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid treatment: a double-blind, placebo-controlled trial. Dig Dis Sci 44:1220–1221

    Article  PubMed  CAS  Google Scholar 

  20. Turunen U, Farkkila, Valtonen V (1998) Long-term treatment of ulcerative colitis with ciprofloxacin. Gastroenterology 117:282–283

    Google Scholar 

  21. Lobo AJ, Burke DA, Sobala GM, Axon AT (1993) Oral tobramycin in ulcerative colitis:effect on maintenance of remission. Aliment Pharmacol Ther 7:155–158

    Article  PubMed  CAS  Google Scholar 

  22. Chapman RW, Selby WS, Jewell DP (1986) Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. Gut 27:1210–1212

    Article  PubMed  CAS  Google Scholar 

  23. Mantzaris GJ, Hatzis A, Kontogiannis P, Triadaphyllou G (1994) Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis. Am J Gastroenterol 89:43–46

    PubMed  CAS  Google Scholar 

  24. Mantzaris GJ, Petraki K, Archavlis E, Amberiadis P, Kourtessas D, Christidou A, Triantafyllou G (2001) A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis. Scand J Gastroenterol 36:971–974

    Article  PubMed  CAS  Google Scholar 

  25. Dickinson RJ, O’Connor HJ, Pinder I, Hamilton I, Johnston D, Axon AT (1985) Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis. Gut 26:1380–1384

    Article  PubMed  CAS  Google Scholar 

  26. Jahanshahi G, Motavasel V, Rezaie A, Hashtroudi AA, Daryani NE, Abdollahi M (2004) Alterations in antioxidant power and levels of epidermal growth factor and nitric oxide in saliva of patients with inflammatory bowel diseases. Dig Dis Sci 49(11–12):1752–1757

    Article  PubMed  CAS  Google Scholar 

  27. Rezaie A, Parker R, Abdollahi M (2006) Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause? Dig Dis Sci (in press)

Download references

Author information

Authors and Affiliations

  1. Faculty of Pharmacy and Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran

    Roja Rahimi & Mohammad Abdollahi

  2. Drug Selecting Committee, Food and Drug Organization, Tehran, Iran

    Shekoufeh Nikfar

  3. Department of Community Health Sciences, Faculty of Medicine, University of Calgary, Calgary, Canada

    Ali Rezaie

  4. Department of Toxicology & Pharmacology, Faculty of Pharmacy, and Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, P.O. Box 14155-6451, Tehran, Iran

    Mohammad Abdollahi

Authors
  1. Roja Rahimi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shekoufeh Nikfar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ali Rezaie
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mohammad Abdollahi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mohammad Abdollahi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rahimi, R., Nikfar, S., Rezaie, A. et al. A Meta-Analysis of Antibiotic Therapy for Active Ulcerative Colitis. Dig Dis Sci 52, 2920–2925 (2007). https://doi.org/10.1007/s10620-007-9760-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-007-9760-1

Keywords

Search

Navigation